Literature DB >> 7634511

Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men.

J Oscarsson1, U Lundstam, B Gustafsson, P Wilton, S Edén, O Wiklund.   

Abstract

OBJECTIVE: Lipoprotein(a) is a lipoprotein fraction associated with atherosclerosis. The serum concentration of lipoprotein(a) has been shown to be mainly genetically determined but recently evidence for hormonal regulation has been presented. The aim of the present study was to investigate the effects of insulin-like growth factor-I on serum lipoproteins, especially lipoprotein(a).
DESIGN: The effects of one week of IGF-I treatment were studied in an open trial.
SUBJECTS: Ten healthy men, who participated in a pharmacokinetic study, were given recombinant human insulin-like growth factor-I (40 micrograms/kg/day) as daily subcutaneous injections. MEASUREMENTS: Serum samples for measurements of lipoproteins were taken after an overnight fast before and after 7 days of treatment.
RESULTS: There was decrease in serum lipoprotein(a) concentration (18.5 +/- 5.5%) in nine of the subjects, and a slight increase in one of the subjects with the lowest concentrations. Also serum apolipoprotein (b) (6.3 +/- 2.2%), serum cholesterol (10.6 +/- 1.8%) and serum triglyceride (14.8 +/- 4.8%) concentrations decreased. An unexpected finding was that fasting serum glucose concentrations increased (13 +/- 4%).
CONCLUSION: Insulin-like growth factor-I is involved in the regulation of lipoprotein(a) concentrations, which might have novel therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634511     DOI: 10.1111/j.1365-2265.1995.tb02699.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.

Authors:  Robert J Ferry; Pinchas Cohen; Lorraine E Levitt Katz
Journal:  Horm Res       Date:  2005-05-09

3.  Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men.

Authors:  Karim Zouaoui Boudjeltia; Brice Faraut; Maria José Esposito; Patricia Stenuit; Michal Dyzma; Pierre Van Antwerpen; Dany Brohée; Luc Vanhamme; Nicole Moguilevsky; Michel Vanhaeverbeek; Myriam Kerkhofs
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

4.  Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE-/- mice.

Authors:  Yuna Shang; Chuanrui Ma; Jing Zhang; Zhongyan Wang; Chunhua Ren; Xin Luo; Rong Peng; Jingfei Liu; Jingyuan Mao; Yang Shi; Guanwei Fan
Journal:  Theranostics       Date:  2020-08-13       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.